AbolerIS Pharma Raises €2.5M in Seed Financing from Newton Biocapital and Turenne Santé/Sham Innovation Santé. 

Read the press release from November 4th, 2020.      

 Read the French press release .

Our Approach 

AbolerIS Pharma will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

schema aboleris -


Dr. Carole GUILLONNEAU Advisor
PhD, Research Director class 2 at CNRS, director of an INSERM team at the Center for Research in Transplantation and Immunology CRTI.
Dr. Ignacio ANEGON
Dr. Ignacio ANEGONAdvisor
MD, Research Director class 1 at INSERM, Director of INSERM 1064 (2008-2018) and co-coordinator of team 2 “Induction of immunological tolerance”. Manager of the platform for genetically modified animals ” Rat Transgenesis and ImmunoPhenomic”.
Dr François-Xavier HUBERT
Dr François-Xavier HUBERTPresident
MD, PhD in immunology. Advisor of international funding agencies and academic societies.

Scientific Advisory Board

Roland BUELOW (PhD)
Roland BUELOW (PhD)
Founder and CEO of Teneobio (Palo Alto, USA). Successful serial entrepreneur, 35 years’ experience in the generation of MAbs.
Director Antibody Therapeutic Center of Oxford University. Developed Campath-1. 45 years of experience in translational and clinical immunology.
Hans-Dieter VOLK (MD)
Hans-Dieter VOLK (MD)
Charité, University of Berlin, 35 years of experience in translational and clinical immunology.
Institute for Medical Research, NY, USA. 45 years of experience in lupus research.